drugset / Trial / NCT04298021
DDR-Umbrella Study of DDR Targeting Agents in Advanced Biliary Tract Cancer
Non-randomizedParallel-groupOpen-labelTreatment
Summary
To assess the effect of AZD6738 and Durvalumab combination or AZD6738 and Olaparib combination in biliary tract cancer patients who have failed to 1st-line chemotherapy.
Timeline
- Start
- 2020-06-25
- Primary completion
- 2024-12-31
- Completion
- 2024-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ceralasertib | Small molecule | 160 mg | — |
| Subject | Ceralasertib | Small molecule | 240 mg | — |
| Subject | Durvalumab | Monoclonal antibody | 1500 mg | Intravenous |
| Subject | Olaparib | Small molecule | 300 mg | — |